SAFEbody is a masking technology that aims to ensure that antibodies are only activated ... its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), which still has modest sales ...

For mRNA vaccines, there are various ways that they can be used against cancer, including in adoptive T-cell therapies, therapeutic antibodies ... and Regeneron’s Libtayo (cemiplimab), a ...

Clinical Trial Supply Agreement Announced with Regeneron for Libtayo (cemiplimab): In February, Immuneering announced a clinical trial supply agreement with Regeneron Pharmaceuticals for its anti-PD-1 ...

The researchers showed “super antibodies” from the man’s blood prevented toxic damage from neurotoxins found in the venoms of 19 different snake species. Scientists in the United States have ...

and efficacy of solnerstotug as both a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab) in patients with advanced solid tumors. Recent updates include ...

and as monotherapy in second-line pancreatic cancer - - Announced clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab ...

Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of solnerstotug as both a monotherapy and in ...

According to Dr. Jacob Glanville from Centivax, antivenom medicines are typically made by injecting small amounts of venom into animals, waiting for their immune systems to product antibodies ...

and as monotherapy in second-line pancreatic cancer - - Announced clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in ...

and efficacy of solnerstotug as both a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) in patients with advanced solid tumors. , Sensei announced preliminary ...